Day-one subcutaneous Leqembi means eligible patients can start treatment with weekly shots at home instead of starting with IV infusions. For family caregivers, that means fewer infusion-center visits but the same need for testing, brain scans, and symptom checks.
Leqembi (lecanemab-irmb) is a prescription antibody treatment for early Alzheimer's that targets amyloid-beta in the brain. The new option is called Leqembi Iqlik. It uses an autoinjector for the first doses, not a drip.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed in 2026?
- Who can receive this starting regimen?
- What does home treatment still require?
- What safety monitoring stays in place?
What changed in 2026?
On July 13, 2026, the FDA approved weekly subcutaneous lecanemab as a starting regimen, so patients no longer must begin with IV infusions, according to Eisai and Biogen in the FDA approval notice. The starting dose is 500 mg once weekly, given as two back-to-back 250 mg autoinjector injections. Supply for starting treatment reached the U.S.
in late August 2026. That change ended the older sequence described by NeurologyLive, where patients completed about 18 months of biweekly IV treatment before they could switch to at-home shots in its report on the prior IV-first rule. At-home dosing had been available since August 2025, but only after IV initiation. Families now discuss shots from the first dose.
Who can receive this starting regimen?
Treatment is for adults with mild cognitive impairment or mild dementia due to Alzheimer's. Patients must also have confirmed amyloid-beta pathology. That is the same early-stage group studied in the trials.
Confirmation still happens at the clinic before the first prescription. Expect memory testing, a diagnosis of the stage, and an amyloid test. A person with moderate or severe dementia, or without amyloid buildup, does not qualify.
What does home treatment still require?
A clinician must watch at least two back-to-back subcutaneous doses before deciding home use by a patient or caregiver is appropriate. That check covers injection technique, storage, timing, and missed-dose plans. Do not plan to give the very first doses alone.
After initiation, maintenance uses a 360 mg autoinjector that takes about 15 seconds. Clinic visits drop, but clinic duties do not end. Use this list for your first appointment:.
- Ask how amyloid status will be confirmed and recorded.
- Ask who supervises the first two shots and where.
- Ask for the MRI dates, after-hours contact, and which symptoms need same-day care.
What safety monitoring stays in place?
Leqembi carries a boxed warning for amyloid-related imaging abnormalities, called ARIA, with brain swelling or bleeding, and it requires a baseline brain MRI plus scheduled follow-up MRIs, according to Practical Neurology in its summary of monitoring and availability. Data presented at the 2026 Alzheimer's Association meeting showed similar drug exposure, amyloid removal, and safety for weekly shots and IV starts. Similar does not mean risk-free.
Call promptly for new neurological symptoms between scans. Keep the MRI appointments even when injections feel routine. Bring a current medication list, especially blood thinners, and ask how they affect bleeding risk.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What Primary Care Patients Should Know About the News
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Primary Care Patients Should Know About the News
- Serious Illness and End-of-Life Dementia Research Priorities in 2026: A 2026 Follow-Up Checklist for Family Caregivers
